Nottingham, United Kingdom

David Michel Adrien Taddei

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 6.6

ph-index = 4

Forward Citations = 161(Granted Patents)


Company Filing History:


Years Active: 2012-2022

Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents

Title: David Michel Adrien Taddei: Innovator in Cancer Treatment

Introduction

David Michel Adrien Taddei is a notable inventor based in Nottingham, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. With a total of 14 patents to his name, Taddei's work is recognized for its potential impact on medical science.

Latest Patents

Among his latest patents is a process for preparing modulators of p300 and/or CBP. This innovative process involves treating specific compounds to generate intermediates that lead to the recovery of a compound with promising modulating activity. This compound has potential utility in treating various cancers, including prostate cancer, hematological cancers, bladder cancer, and lung cancer. Another significant patent involves pharmaceutical compounds that are arylimidazolyl isoxazoles, which also modulate p300 and/or CBP activity, specifically targeting prostate cancer.

Career Highlights

Throughout his career, Taddei has worked with several companies, including Respivert Limited and Cellcentric Limited. His experience in these organizations has contributed to his expertise in pharmaceutical development and innovation.

Collaborations

Some of his notable coworkers include Stuart Thomas Onions and Neil Anthony Pegg. Their collaboration has likely fostered an environment of innovation and creativity in their respective projects.

Conclusion

David Michel Adrien Taddei stands out as an influential inventor in the pharmaceutical industry, particularly in cancer treatment. His patents reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…